some perspectives on a draft pharmacovigilance protocol reference to hiv aids l.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
Some Perspectives on a Draft Pharmacovigilance Protocol-reference to HIV/AIDS PowerPoint Presentation
Download Presentation
Some Perspectives on a Draft Pharmacovigilance Protocol-reference to HIV/AIDS

Loading in 2 Seconds...

play fullscreen
1 / 29

Some Perspectives on a Draft Pharmacovigilance Protocol-reference to HIV/AIDS - PowerPoint PPT Presentation


  • 132 Views
  • Uploaded on

Some Perspectives on a Draft Pharmacovigilance Protocol-reference to HIV/AIDS. I Ralph Edwards. Identifying ADRs in Africa – Special Challenges: general . Limited access to health services Limited diagnostic capabilities Over-burdened health care system & staff

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Some Perspectives on a Draft Pharmacovigilance Protocol-reference to HIV/AIDS' - lenci


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
some perspectives on a draft pharmacovigilance protocol reference to hiv aids

Some Perspectives on a Draft Pharmacovigilance Protocol-reference to HIV/AIDS

I Ralph Edwards

identifying adrs in africa special challenges general
Identifying ADRs in Africa – Special Challenges: general
  • Limited access to health services
  • Limited diagnostic capabilities
  • Over-burdened health care system & staff
  • Significant resource restraints
  • Communication barriers
identifying adrs in africa special challenges hiv aids
Identifying ADRs in Africa – Special Challenges: HIV/AIDS
  • Patients need to continue drugs
    • ADRs common and troublesome
  • Need to treat ADRs
  • Combinations of drugs
    • Which drug?
  • Disease and complications and ADRs affect multiple overlapping body systems
introduction
Introduction
  • Much information and experience in USA/EU, but
    • Different drug combinations used
    • Population and disease burden varies
  • Inadequate infrastructure in place in many 3x5 roll-out countries to monitor safety
definition adverse event vs adverse reaction
Definition: Adverse Event vs. Adverse Reaction
  • Adverse Drug Reaction
    • A noxious and unintended response to a medicine which occurs at doses normally used in man for treatment, prophylaxis, diagnosis or modification of physiological function.
  • Adverse Event:
    • untoward medical occurrence which does not necessarily have to have a causal relationship with the treatment
adverse drug reaction vs adverse event
Adverse Drug Reaction vs.Adverse Event

Adverse Event

Adverse Drug Reaction

(event attributed to drug)

Diseases

Diet

Other

factors

Genetics

All Spontaneous

reports

Other Drugs

Events not attributed to drug

Environment

Compliance

definition serious adverse event
Definition: Serious Adverse Event
  • Any untoward medical occurrence that at any dose results in:
    • Death
    • Is life-threatening
    • Requires or prolongs patient hospitalisation
    • Results in permanent disability/incapacity or is
    • A congenital anomaly/ birth defect
    • Other medically significant event (e.g. blood dyscrasias, seizures)
    • Does not include NON-serious events that have the POTENTIAL to be SERIOUS if allowed to progress further, nor SEVERE events
objectives of a basic system
Objectives of a Basic System
  • Signal detection for concerns about the safety of drugs
  • Assessment of signals to evaluate:
    • causality,
    • clinical relevance,
    • frequency and distribution in certain population groups
  • Communication and recommendations to authorities and public
  • Appropriate response/action
    • in terms of drug registration, drug use and/or training and education for professionals and the public
  • Measurement of outcome of response/action taken
    • (e.g. reduction in risk of signal, improved drug use, or improved outcome of patients with ADR)
the pharmacovigilance process
The pharmacovigilance process

Follow up

Case reports

Action

Communication

Case database

Signal analysis

Signal detection

why monitor all drugs
Why Monitor ALL drugs?
  • Create an awareness of safety issues and drugs
  • To encourage health professionals to share concerns about drugs
  • To determine the concerns health professionals have over drugs and their best use
    • Including interactions
  • To react to with helpful information to improve therapy
  • Minimise undue concern about safety of therapies known to cause ADRs
    • Eg. Anti-retrovirals
  • Allow for comparison of reporting rates among different therapeutic classes of medicines
elements of the basic system
Elements of the Basic system
  • Possible general system:
    • Peripheral health facilities
      • (spontaneous reporting of drugs used in general medical practice)
    • Tertiary care facilities and ADR Centre
      • (Spontaneous reporting and SAEs investigated and intensive monitoring programmes. Special investigations)
    • Antenatal and delivery clinics
      • (Pregnancy-related SAE’s and congenital anomalies reported)
    • Public health Programmes
      • HIV/AIDS, Malaria etc.
slide12
Peripheral Health Care Facilities:E.g. health posts, clinics, outreach centres, dispensaries, outpatient departments
  • Proper prescribing, counseling and administration of meds
    • Inform patients to return in case of further or ongoing illness
    • Counsel patients on how to take meds
    • 1 hour observation post-medication
  • Completion of SAE form in the event of suspected reaction
  • Send form to district/state/national level coordinator (depending on infrastructure)
  • Patients referralto hospital if necessary (with referral note informing of suspected ADR)
  • Management of non-serious reactions
evaluation investigation team
Evaluation/Investigation Team
  • General or special or geographical (??)
    • May be comprised of only 1 person
  • Weekly review of all reports received
    • Follow-up all/specific SAEs
      • Home and facility visit if warranted
      • Return to facility within 2 weeks for investigation
  • Review ADR forms and Investigation Team report forms
  • Aggregation into monthly report
  • Aggregates and individual reports forwarded to national co-ordinator
secondary tertiary care facilities e g hospitals health centres others
Secondary/Tertiary Care FacilitiesE.g. Hospitals, health centres (others?)
  • Investigate any patient attending tertiary care hospitals due to suspected ADR (self-reported, detected in hospital or referred from peripheral health workers) should be investigated
  • Intensive monitoring in specifically selected facilities
    • Event monitoring and epidemiological studies
antenatal clinics and delivery services
Antenatal Clinics and Delivery Services
  • Report congenital anomalies using SAE reporting form
detection of serious drug reactions
Detection of serious drug reactions

(if abnormal lab tests,

eg agranulocytosis,

interview patient for

detailed history)

Case-finding

or cohort

intensive

Laboratory and clinical

investigations

HOSPITAL

Generic form

Follow-up with detailed report and causality rating,

HEALTH CENTERS

PRIVATE CLINICS

spontaneous

DISPENSARIES

Shops, traditional healers, other health professionals

roles and responsibilities
Roles and Responsibilities
  • Establish roles and responsibilities of
    • Patient
    • Clinic staff
    • Traditional Healers and other informal providers
    • District/state/national investigation team
    • National pharmacovigilance co-ordinator
    • Expert safety review panel
    • Malaria control programme
    • Drug regulatory authority
    • Media
    • International agencies (WHO, UMC, etc)
from data to signal analysis international
From data to signal analysis:international

Follow up

National case reports

Action

Communication

WHO database

UMC Signal detection

Signal analysis

the importance of denominators
The Importance of Denominators
  • Denominator: estimated figure of drug use
    • for estimating frequency of events
  • Comparisons between drugs difficult and VERY problematic without rates
    • Often use a comparator/control drug within the system to determine whether lack of signals due to underreporting or real absence of signal
examples of denominators
Examples of Denominators
  • Drug procurement figures from central medical stores of MOH
  • Drug distribution data from EDPs, national drug suppliers/distributors, or manufacturers
  • Drug records at importation from customs
  • Notification reports from disease surveillance programmes
    • ?e.g. HIV/AIDS
  • Drug procurement records from wholesalers in private sector
  • Supplementary drug surveys (e.g. treatment seeking behaviour, drug utilisation, or surveys of drug vendors.)
adopting and adapting the forms
Adopting and Adapting – the forms
  • ADR report form
  • Evaluation and follow-up form
  • Special investigations
    • Public health programmes e.g. HIV/AIDS
    • Congenital anomaly registers
    • Etc.
  • Study protocols
communication general
Communication: General
  • All reports must be acknowledged
    • Reporters must feel a valued part of the system
  • Useful feedback must be given
    • Specific to the case if necessary
    • General, in the form of periodic reports
communication hiv aids
Communication: HIV AIDS
  • Must allow treating health professionals best information on effectiveness v. risks
    • Globally and in own population
  • Give them, and patients, knowledge and confidence to continue therapy in spite of some ADRs
  • Give information on best avoidance, minimisation, and treatments for ADRs
issues for discussion and consideration i
Issues for discussion and consideration (I)
  • Is this system feasiblein your country?
    • Should it be modified/simplified?
  • When should you be encouraging reporting of events or reactions
  • Should you encourage reporting of serious events/reactions only orinclude non-serious as well?
    • (This draft does not discourage non-serious reports)
  • Based on resources, size of country and nature of public health structures– is a special investigation team needed?
    • Could a ‘generic’ national-level or state-level investigation team suffice?
  • Can the proposed reporting flow be adapted to your country setting?
issues for discussion and consideration ii
Issues for discussion and consideration (II)
  • Should the forms be printed in single or duplicate? If duplicate who will each copy go to?
  • What should be the timelines for submitting initial reports, investigations reports, aggregate reports? And to whom
    • supervisor, national coordinator, special investigation team etc.
  • Which reports to be investigated? All suspected ADRs, clusters ? Unexpected? Unusual? Significantly affecting compliance?
issues for discussion and consideration iii
Issues for discussion and consideration (III)
  • Consider the functions and activities of each individual/organisation in your proposed reporting flow
  • What would be an accurate denominator for drug use for HIV/AIDS treatments and a comparator/s
  • What do you think are the critical success factors to achieve the system and its objectives?
  • How can these critical success factors be achieved in your country?
critical success factors
Critical Success Factors
  • Literacy of reporters
  • Clearly defined responsibilities
  • Adequate training and education
  • Public awareness of the new medicine
  • Public awareness on reporting safety problems of all medicines
  • Awareness of pharmacovigilance system within informal sector
    • Community & religious leaders, shopkeepers, traditional healers, community health workers and school teachers
  • Quality control of laboratories
  • Open communication between public, health care providers and policy makers
    • Judicious and pro-active use of the media, professional and general
  • Presence of national coordinator/s